Liver Fat Articles & Analysis
7 news found
Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver CongressTM 2022, to be held in London, UK on June 22-26, 2022. ...
The 12-week Phase 1b NAFLD trial is designed to assess the effects of pemvidutide on liver fat in subjects with obesity or overweight and liver fat content of 10% or greater as measured by MRI-PDFF. ...
” HemoShear’s REVEAL-Tx™ platform has been utilized to create a model of NASH that recapitulates hallmark features of liver fat build up, increased cell stress and inflammation, and extracellular matrix signaling that was published in the Journal of Clinical Investigation Insight. In addition, Nature Scientific Reports published the ...
With 100 million Americans affected by fatty liver disease, one-fifth will progress to a more severe form of the condition and are at further risk of developing cirrhosis and liver cancer. ...
In addition, patients showed an average of 31% reduction in liver fat along with significant reductions in body weight. There were no procedure-related serious adverse events. ...
Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date. LEXINGTON, Mass., August 6, 2020 – Fractyl Laboratories Inc. ...
In addition to the glycemic benefits observed in type 2 diabetes in earlier studies, there was also significant improvement in liver disease parameters, including significant reduction in liver fat, and lipid profiles. ...